AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Mineralys Therapeutics, Inc.
Video analysis: MLYS
All videosNo video analysis for this stock yet. Request one from our team.
News: MLYS
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering an aggregate of 29,760 shares and inducement restricted stock unit awards covering an aggregate of 22,320 shares of Mineralys common stock to two new non-executive employees.
Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS
Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 64.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,000 shares of the company's stock after selling 53,500 shares during the period. Greenland Capital Management LP's holdings
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with Baxfendy, MLYS's focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction.
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS
Canada Pension Plan Investment Board bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 51,400 shares of the company's stock, valued at approximately $1,387,000. Canada Pension Plan Investment Board owned 0.06%
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,887,038 shares of the company's stock, valued at approximately $158,832,000. BlackRock Inc. owned approximately 7.14% of Mineralys Therapeutics
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys' Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys' newly appointed Chief Medical Officer.
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
